联系客服

600535 沪市 天士力


首页 公告 600535:天士力关于2021年第一季度主要经营数据的公告

600535:天士力关于2021年第一季度主要经营数据的公告

公告日期:2021-04-24

600535:天士力关于2021年第一季度主要经营数据的公告 PDF查看PDF原文

        证券代码:600535        证券简称:天士力        编号:临 2021-025 号

                    天士力医药集团股份有限公司

                关于 2021 年第一季度主要经营数据的公告

            本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述

        或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。

            根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业信

        息披露指引第七号——医药制造》及《关于做好上市公司 2021 年第一季度报告

        披露工作的通知》相关要求,现将公司 2021 年第一季度主要经营数据披露如下:

        一、报告期内分行业经营数据

                                                        单位:元币种:人民币

                      主营业务收入                                主营业务成本                      毛利率(%)

 行业                                      增长率                                      增长率  2021  2020  增长
        2021 年 1 季度    2020 年 1 季度    (%)    2021 年 1 季度    2020 年 1 季度    (%)  年 1    年 1    率
                                                                                                  季度  季度

 医药  1,454,617,219.31  1,377,444,880.32    5.60    392,712,675.85    438,745,987.50  -10.49  73.00  68.15  4.85
 工业

 医药    292,775,182.70  2,547,324,955.11  -88.51    222,389,756.71  2,298,905,396.12  -90.33  24.04  9.75  14.29
 商业

 合计  1,747,392,402.01  3,924,769,835.43  -55.48    615,102,432.56  2,737,651,383.62  -77.53  64.80  30.25  34.55

                                                        单位:元币种:人民币

                                                              营业收入比  营业成本比  毛利率比上
 分治疗领域      营业收入        营业成本    毛利率(%)  上年增减  上年增减(%) 年增减(%)
                                                                  (%)

心脑血管        930,293,155.44    238,621,512.46      74.35      10.37        -6.95        4.78

肝病治疗          97,317,954.86    18,838,835.89      80.64      32.33        8.22        4.31

抗肿瘤          148,651,762.05    26,554,078.44      82.14      -6.61        20.82        -4.05

感冒发烧        100,887,070.70    47,701,346.89      52.72      -40.71      -48.17        6.80

其他            177,467,276.26    60,996,902.17      65.63      34.74        19.87        4.26

医药工业合计    1,454,617,219.31    392,712,675.85      73.00        5.60      -10.49        4.85

医药商业合计    292,775,182.70    222,389,756.71      24.04      -88.51      -90.33        14.29

合计          1,747,392,402.01    615,102,432.56      64.80      -55.48      -77.53        34.55


                                                        单位:元币种:人民币

  分产品        营业收入          营业成本      毛利率  营业收入比  营业成本比  毛利率比上
                                                    (%)  上年增减(%) 上年增减(%) 年增减(%)

中药          1,040,316,948.98    299,565,124.75  71.20        3.45      -12.76        5.35

生物药            49,998,974.17    18,741,215.47  62.52        35.01      -23.59      28.75

化学制剂        338,756,075.35    63,944,570.53  81.12        7.24        8.52      -0.22

化学原料药        25,545,220.81    10,461,765.10  59.05        34.99      -12.29      22.08

医药工业小计  1,454,617,219.31    392,712,675.85  73.00        5.60      -10.49        4.85

医药商业小计    292,775,182.70    222,389,756.71  24.04      -88.51      -90.33      14.29

合计          1,747,392,402.01    615,102,432.56  64.80      -55.48      -77.53      34.55

            报告期内,肝病治疗产品收入较上年同期增长 32.33%,主要系水林佳销量

        增长所致;感冒发烧产品收入较上年同期下降 40.71%,主要由于上年受疫情影响,

        感冒发烧药产品销量增加;其他产品收入较上年同期增长 34.74%,主要系他达拉

        非片和安宫牛黄丸销量增长所致。

            报告期内生物药收入较上年同期增长 35.01%,主要系普佑克销量增加所致;

        化学原料药收入较上年同期增长 34.99%,主要系尼可地尔销量增长所致。

            医药商业收入比上年同期减少,主要系公司 2020 年 8 月处置天士营销所致。

            二、报告期内分地区经营数据

                                                单位:元币种:人民币

              地区      本期累计主营业务收入    上年同期累计主营业务收入  增长比例(%)

          天津市            2,686,904,615.78            2,391,599,360.35          12.35

          北京市                                          107,470,957.78        -100.00

          上海市                49,998,974.17              36,803,825.79          35.85

          广东省                6,056,573.78              203,941,607.19          -97.03

          山东省                62,841,440.33              93,256,678.50          -32.61

          陕西省                19,466,279.51              988,177,357.66          -98.03

          湖南省                                          227,049,834.52        -100.00

          辽宁省              226,296,430.08              590,607,977.41          -61.68

          江苏省              294,766,438.02              283,145,738.98            4.10


    地区      本期累计主营业务收入    上年同期累计主营业务收入  增长比例(%)

 山西省                                          452,119,447.64        -100.00

 其他                  24,454,945.62              28,739,976.58          -14.91

 小计              3,370,785,697.29            5,402,912,762.40          -37.61

 抵消              1,623,393,295.28            1,478,142,926.97            9.83

 合并              1,747,392,402.01            3,924,769,835.43          -55.48

  注:上表中地区分布以公司所在地划分。

  报告期内上海市销售收入同比上升,主要系普佑克销量增加所致;其他地区销售收入同比下降主要系公司 2020 年 8 月处置天士营销所致。

  本公告之经营数据未经审计
[点击查看PDF原文]